Neural tube defects Petra M. Klinge, MD Associate Professor of - - PowerPoint PPT Presentation

neural tube defects
SMART_READER_LITE
LIVE PREVIEW

Neural tube defects Petra M. Klinge, MD Associate Professor of - - PowerPoint PPT Presentation

Neural tube defects Petra M. Klinge, MD Associate Professor of Neurosurgery Warren Alpert Medical School of Brown University Overview Epidemiology, Definition, Classification Pathophysiology and associated Disorders: Hydrocephalus and


slide-1
SLIDE 1

Neural tube defects

Petra M. Klinge, MD Associate Professor of Neurosurgery Warren Alpert Medical School of Brown University

slide-2
SLIDE 2

Overview

  • Epidemiology, Definition, Classification
  • Pathophysiology and associated Disorders:

Hydrocephalus and Chiari II Malformation

  • Pre- and Postnatal diagnosis
  • Surgical Treatment
  • Aspects of Fetal Surgery: Results of the MOMS

Trial

  • Aspects of Translational Research
slide-3
SLIDE 3

Epidemiology

 Spina bifida is one of the most common

birth defects,  Worldwide incidence of 1–2 cases per 1000 births, but certain populations have a greater risk.  Highest incidence in Ireland and Wales  More Common if Females

 United States, the average incidence is 0.7 per 1000 live births.  Higher on the East Coast than on the West Coast,  Higher in whites (1 case per 1000 live births) than in African Americans (0.1–0.4 case per 1000 live births).

slide-4
SLIDE 4

Spina bifida and neural tube defects: Definition and Classification

– Open (aperta):

  • Meningocele: 5%;

CSF and meninges

  • Myelomeningocele: 95%;

cord and cauda equina tissue extruded

– Closed (occulta):

50% have cutaneous stigmata ABOVE the gluteal fold

  • Lipomyelomeningocele
  • Filum terminale lipoma
  • “Fatty filum”
  • Dermoid sinus and Dermoid tumors
slide-5
SLIDE 5

Overview

  • Definition, Classification
  • Pathophysiology and associated Disorders:

Hydrocephalus and Chiari II Malformation

  • Pre- and Postnatal diagnosis
  • Surgical Treatment
  • Aspects of Fetal Surgery: Results of the MOMS Trial
  • Aspects of Translational Research
slide-6
SLIDE 6

Pathophysiology: Defect of neural tube Formation

Weeks 3-4 Three phases:

– Neurulation – Canalization – Retrogressive differentiation

slide-7
SLIDE 7

Spina bifida: :Hydrocephalus

  • 80-95% incidence of hydrocephalus in

myelomeningocele

– 100% of 35 thoracic lesions – 88% of 114 lumbar lesions – 68% of 40 sacral lesions

Rintoul et al. Pediatrics 190:409-13, 2002.

  • Significant in 20% at birth
slide-8
SLIDE 8

Spina bifida: Chiari II Malformation

  • 99% myelomeningocele patients have radiographic Chiari II; only those

with symptoms (1/3 by age 5) require treatment

  • Responsible for 15-20% deaths in pediatric myelomeningocele patients

(respiratory failure)

  • Disruption of the CSF circulation at the level of the Cisterna magna:

SYRINGOMYELIA!

slide-9
SLIDE 9

9

 Race & Ethnicity.  Family history of NTD.  Folate deficiency.  Some medications (valproic acid).  Maternal Age.  Diabetes.  Obesity.  Increased body temperature.

GENETICS:

Spina bifida and neural tube defects: Risk factors

 Davidson CM, Northrup H, et al. Genes in Glucose Metabolism and Association With Spina Bifida. Reproductive Sciences, Jan 2008; vol. 15: pp. 51 – 58. Mutations in VANGL1 associated with neural-tube defects . Kibar Z, Torban E. N. Engl. J.

  • Med. 2007:. 356 (14): 1432–7.

Mutations in Genes associated with Folate metabolism.

slide-10
SLIDE 10

Overview

  • Definition, Classification
  • Pathophysiology and associated Disorders:

Hydrocephalus and Chiari II Malformation

  • Pre- and Postnatal diagnosis
  • Surgical Treatment
  • Aspects of Fetal Surgery: Results of the MOMS Trial
  • Aspects of Translational Research
slide-11
SLIDE 11

Spina bifida: Pre-natal MRI Imaging

slide-12
SLIDE 12

Spina bifida “aperta”: Myelomeningocele defect

  • Posterior Vertebral Defect
  • Thecal Sac
  • Cord Extruded into the Sac

(Placode) : plate of embryonic epithelial cells , e.g. the spinal cord!

slide-13
SLIDE 13

Spina bifida „occulta“

Watch for cutaneus stigmata! Dimple, Skin hemangioma, Subcutaenous lipomas, „Tails“, Skin tracts MRI Imaging: „Tethered Cord“

slide-14
SLIDE 14

Hydrocephalus: MRI Imaging

Imaging : Ventriculomegaly Pediatric characteristics: Selective thinning of the occipital lobe!

– Yielding nature of the cranial vault

– Rigid nuclear masses (basal ganglia) in the frontal lobe

Ventricular index > 0.33

Head Circumference Monitoring!

slide-15
SLIDE 15

Serial HUS in neonatal H.

Intestinal perforation & positive blood cultures: E-coli, Pseudomonas and Candida Glabrata

slide-16
SLIDE 16

Overview

  • Definition, Classification
  • Pathophysiology and associated Disorders:

Hydrocephalus and Chiari II Malformation

  • Pre- and Postnatal diagnosis
  • Surgical Treatment
  • Aspects of Fetal Surgery: Results of the MOMS Trial
  • Aspects of Translational Research
slide-17
SLIDE 17
  • Closure within 24 hours:

No evidence exist that immediate or urgent closure of a MMC improves neurologic function BUT reduces risk of infection (after 36 hours wound colonization)

17

Surgical technique

(Interdisciplinary_Neurosurg &Plastic Surg): Placode dissected free of arachnoid and allowed to drop into spinal canal Dura dissected free of skin and lumbodorsal fascia, and closed, Fascia closed Skin closed

CSF

Placode

Meninges SKIN FASCIA

Treatment : MMC

slide-18
SLIDE 18

Sharp microdissection of the placode area

slide-19
SLIDE 19

Treatment: Hydrocephalus

  • Temporary Spinal fluid „drainage“

(Lumbar puncture or external ventricular drainage, Reservoir)

  • Shunt
  • ETV (Endoscopic third ventriculostomy)
  • Weight > 2.5 kg
  • No active infection
  • Medically stable
slide-20
SLIDE 20

Adjustable valve types

Low pressure range: < 60-70mmH20 (5 mmHg) Medium pressure range: 70-120mmH20 (5 –8 mmHg) High pressure range: 120- 200 mmH20 and above (8-15 mmHg)

slide-21
SLIDE 21

Endoscopic 3rd ventriculoscopy

slide-22
SLIDE 22

Treatment: Chiari II

slide-23
SLIDE 23

Overview

  • Definition, Classification
  • Pathophysiology and associated Disorders:

Hydrocephalus and Chiari II Malformation

  • Pre- and Postnatal diagnosis
  • Surgical Treatment
  • Aspects of Fetal Surgery: Results of the MOMS Trial
  • Aspects of Translational Research
slide-24
SLIDE 24

Rationale for Fetal Surgery

  • Despite improved pre-natal diagnostics and health care:

Incidence of Spina bifida has stabilized. 3.4/10000 life births US

  • Classic treatment is palliative.
  • Death rate 10%
  • Fetal monitoring _ shows evidence of progression

(hydocephalus, hindbrain herniation, reduced LE movements etc.)

  • Translational evidence exsits (animal studies report improved

functional outcome and reduced CHIARI FORMATION: Fetal sheep 1993-2003)

  • Health care burden from surviviors since implementation of

shunt (Joseph H. Piatt Jr, J Neurosurg Pediatrics 6:515-525 2010)

slide-25
SLIDE 25

Fetal surgery: Hydrocephalus

  • Ventriculo-amniotic shunts or repeat cephalocentesis

attempted in 1980s, abandoned because of poor

  • utcomes.
  • Incidence of associated nervous system or other

anomalies between 70-84%, most not appreciated prenatally.

  • Shunt obstruction or migration.
  • No clear benefit, as progressive ventriculomegaly not

thought to be life-threatening or brain-injuring given capacity of neonatal skull to expand.

slide-26
SLIDE 26

Fetal Surgery: Myelomeningocele

1. Pfannenstiel incision to deliver gravid uterus outside abdomen 2. Fetus and placenta located by ultrasound, and 6 cm hysterotomy incision made 3. Amniotic fluid aspirated and reserved 4. Fetus positioned within uterus so that myelomeningocele sac in center of incision (Standard MMC repair) 5. Uterus closed in layers with 1-0 chromic suture 6. Amniotic fluid replaced before last stitch placed 7. Fibrin glue applied to suture line

slide-27
SLIDE 27

Overview

  • Definition, Classification and

Pathophysiology

  • Diagnosis and Surgical Treatment
  • Aspects of Fetal Surgery
  • Results of the MOMS Trial
  • Aspects of Translational Research
slide-28
SLIDE 28

Management of Myelomeningocele Study (NEJM 2011)

  • 5-year, multicenter, randomized controlled trial of

200 patients began in February 2003

  • Patients must enroll by their 25th week of

pregnancy

  • Half assigned to postnatal surgery, and half to

prenatal

  • Both surgery types done at one of three designated

centers (UCSF, CHOP, Vanderbilt)

  • Sponsored by the National Institute of Child

Health and Human Development

slide-29
SLIDE 29

Study design

  • Maternal inclusion: US citizen, > 18 years, weight

limit, 19-26 weeks of gestation

  • Fetal inclusion:T1-S1, Chiari II
  • RANDOMIZATION: Pre vs. Postnatal repair
  • CESAREAN SECTION at 37 weeks
  • Outcome at 12 and 30 months (primary = fetal

and neonatal death/criterai for shunt) and (secondary=mental and motor function)

slide-30
SLIDE 30

Results at 12 and 30 months F/UP

  • N=183 (2003-2010)
  • Maternal (30%) complications in pre-natal repair

associated with the hysterotomy

  • Fetal (13%) complications with prematurity: <30 weeks of

gestation!

  • BUT: Outcome improved in Pre- vs. Postnatal repair:

– 68% vs. 98% development of hydrocephalus – 40% vs. 82% need of shunt – 36% vs. 4% no Chiari II – Improved functional level vs. Anatomical level 32% vs. 12% – Walking independently at 30 months: 42% vs. 21%

slide-31
SLIDE 31

Bigger Question

  • Yet,risk of prematurity
  • Is a decreased need for shunting enough to justify

the risks of prematurity and death?

  • No clear benefit in cognition?
  • Policy of current counseling… (Europe
  • vs. US)!!!
slide-32
SLIDE 32

Overview

  • Definition, Classification
  • Pathophysiology and associated Disorders:

Hydrocephalus and Chiari II Malformation

  • Pre- and Postnatal diagnosis
  • Surgical Treatment
  • Aspects of Fetal Surgery: Results of the MOMS Trial
  • Aspects of Translational Research:

Diagnose and Target the Metabolic aspects of the Disease!